HSBC Mutual Fund Pharma Fund - Regular Plan - Growth

HSBC Mutual Fund Pharma Fund - Regular Plan - Growth investment objective and strategy

HSBC Mutual Fund Pharma Fund - Regular Plan - Growth ka primary objective hai pharma sector mein long-term capital appreciation achieve karna. Ye fund equity mutual fund category mein aata hai aur iski investment strategy equity shares aur equity-related securities par focus karti hai. Is fund ko select karne wale investors un logon ke liye sahi hai jo high growth aur high risk tolerance ke saath long-term investing mein interested hain. Agar aapko pharma sector ki potential samajh hai aur aap risky assets mein invest karne ke liye ready hain, toh yeh fund aapke liye suitable ho sakta hai.

HSBC Mutual Fund Pharma Fund - Regular Plan - Growth yearly return performance

HSBC Mutual Fund Pharma Fund - Regular Plan - Growth ki performance kaafi interesting hai. Is fund ne pichle 1 saal mein 0% return diya hai, jo ki benchmark Nifty Pharma TRI ke saath compare karke dekha jaye toh kaafi disappointing hai. Pichle 3 saal aur 5 saal mein bhi is fund ne 0% return diya hai. Iska matlab hai ki fund manager Cheenu Gupta ne pichle kuch saalon mein kuch khaas nahi kiya hai, jo ki investors ke liye ek concern ho sakta hai. Lekin, agar aap long-term perspective se dekhte hain, toh aapko fund ki performance ko market volatility aur sectorial trends ke context mein samajhna padega. Ye fund market ke fluctuations se kaafi impact hota hai, aur isme volatility dekhne ko milti hai, jo investors ke liye risk ko badha sakti hai. Dekha jaye toh, agar aap consistent returns ki talash mein hain, toh aapko shayad is fund ko behtar options ke saath compare karna pade.

HSBC Mutual Fund Pharma Fund - Regular Plan - Growth top holdings and portfolio allocation

Ab baat karte hain HSBC Mutual Fund Pharma Fund - Regular Plan - Growth ki top holdings ki. Is fund ki sabse badi holdings mein Sun Pharmaceutical Industries Ltd. (20.5%), Dr. Reddy's Laboratories Ltd. (12.8%), Cipla Ltd. (10.4%), Divi's Laboratories Ltd. (9.8%), aur Torrent Pharmaceuticals Ltd. (7.2%) shamil hain. Ye holdings fund ki overall portfolio strategy ko darshati hain, jo ki pharma sector ke major players par focused hai. Jaise ki aap dekh sakte hain, top 5 holdings mein hi fund kaafi zyada allocation hai, jo iski concentrated approach ko darshata hai. Portfolio allocation kaafi diversified hai, lekin khaas taur par pharma sector ke andar. Ye risk ko samajhne ke liye zaroori hai, kyunki agar kisi particular company ya sector mein downturn aata hai, toh fund ke returns par iska seedha prabhav pad sakta hai. Investors jo diversify karna chahte hain, unhe dhyaan rakhna hoga ki ye fund high concentration risk ke saath aata hai, jo ki market volatility ke waqt significant impact daal sakta hai.

HSBC Mutual Fund Pharma Fund - Regular Plan - Growth – risk level aur volatility

HSBC Mutual Fund Pharma Fund - Regular Plan - Growth ka riskometer "Very High" hai, jo ki is fund ke liye ek significant risk level darshata hai. Iska matlab hai ki investors ko is fund mein invest karne se pehle apne risk tolerance ko achhe se samajhna hoga. Volatility bhi is fund ka ek important aspect hai. Agar aap market ke fluctuations ko handle nahi kar sakte, toh shayad ye fund aapke liye sahi nahi hai. Sharpe ratio data available nahi hai, lekin is fund ki high volatility kaafi saare investors ko cautious approach lene par majboor kar sakti hai. Agar aap risk se bhare investments mein comfortable hain aur long-term capital appreciation ki talash mein hain, toh aap is fund ko consider kar sakte hain. Lekin, agar aap conservative investor hain, toh shayad aapko behtar options ki taraf dekhna chahiye.

HSBC Mutual Fund Pharma Fund - Regular Plan - Growth pros and cons for investors

• Pros:
  • Potential for high returns in pharma sector
  • Strong focus on leading pharma companies
  • Suitable for aggressive investors seeking growth
  • Long-term capital appreciation potential
• Cons:
  • High risk and volatility associated
  • 0% returns over 1, 3, and 5 years
  • Concentrated portfolio increases risk